I

Intuitive Surgical

Builds robots for minimally invasive surgery

Senior Clinical Research Engineer - Future Forward

Full-Time
$158.2k - $267.9k/yr+ Incentives + Equity
Senior, Expert
Bachelor of Science (BS)
Sunnyvale, CA, USA
In PersonMust commute or relocate to Sunnyvale, California. Up to 30% travel, including some international travel, is required.
Biology & BiotechBiomedical Engineering & Medical Devices

About the job

Requirements
  • Fluency in medical procedure terminology and sound knowledge of anatomy.
  • Ability to understand complex robotic systems and software algorithms.
  • Experience working in an operating room or interventional suite environment.
  • Experience collaborating with physicians and collecting feedback on clinical use of the product.
  • Mechanical and technical aptitude, with spatial-relations ability and an understanding of complex mechanical products.
  • Analytical capability and practical skills to develop and test a clinical hypothesis and draw succinct conclusions.
  • Teamwork and cross-disciplinary collaboration skills to support timely project success.
  • Demonstrated ability to recognize critical issues and drive them to closure through coordinated action.
  • Experience with product development and Design Controls.
  • Effective verbal, written, and presentation communication skills.
  • Ability to work independently with minimal supervision.
  • Ability to react quickly under pressure.
  • A minimum of a B.S. in Biomedical Engineering, Mechanical Engineering, or a similar field.
  • At least 8 years of related experience in clinical engineering and/or product development within the medical device industry.
  • Availability to work full-time and commute or relocate to Sunnyvale, California.
  • Willingness to travel up to 30%, including some international travel.
  • Current proof of vaccination against certain diseases may be required depending on the role and/or customer.
  • Some roles may require compliance with U.S. export controls, including obtaining an export license or operating under a Technology Control Plan.
Responsibilities
  • Lead the design and development of new product concepts before commercial launch using clinical, scientific, and technical expertise.
  • Research disease states and medical technologies associated with new business opportunities and develop expertise in new products and their clinical applications.
  • Collaborate with marketing partners and clinicians to identify and understand marketing needs.
  • Work with key opinion leaders, subject matter experts, and other stakeholders to identify clinical goals and translate needs into user-centric designs for platforms, procedures, instruments, and accessories.
  • Collaborate with engineers and physicians to define and evaluate clinical performance goals and potential safety and usability risks for products in early-phase development.
  • Develop and execute clinical derisking pathways, including pre-clinical and clinical feasibility studies, to advance technology and prepare it for commercial launch.
  • Conduct design-iteration assessments of products internally and with external key opinion leaders.
  • Develop and execute a preclinical evaluation strategy before human trials and regulatory submissions.
  • Provide subject matter expertise for user-manual and training-documentation development.
  • Support regulatory documentation and submissions.
  • Identify potential product enhancements and new product ideas through analytical evaluation.
  • Lead and execute early-stage feasibility clinical studies, pilot clinical trials, and pivotal clinical trials to support technology development, regulatory strategies, and reimbursement strategies.
  • Identify and drive product enhancements and new product ideas by analyzing the clinical needs of physicians and users.
  • Collect and analyze clinical-study insights to inform product requirements and training needs, and manage clinical risks in accordance with quality-management systems.
  • Design, develop, and execute clinical evaluations of prototypes and translate feedback to the engineering team to accelerate technology development.
  • Develop intellectual property for novel clinical applications and technologies.
  • Perform other duties required to support the company’s overall strategy and goals.
Desired Qualifications
  • Experience with on-site clinical trial support.
  • Experience with commercial product launch.
  • Familiarity with intellectual property development and patent assessment.

About the company

Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
  • Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
  • Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.

What critics are saying

  • Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
  • Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
  • Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.

What makes Intuitive Surgical unique

  • Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
  • It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
  • Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.